Coverage with evidence development, only in research, risk sharing or patient access scheme?: A framework for coverage decisions

Simon Mark Walker; Mark Sculpher; Karl Philip Claxton; Stephen John Palmer

Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions

Simon Mark Walker, Mark Sculpher, Karl Philip Claxton, Stephen John Palmer

Research output: Book/Report › Other report

Abstract

Until recently, purchasers’ options regarding whether to pay for the use of technologies have been binary in nature: a treatment is covered or not covered. However, policies have emerged which expand the options - for example, linking coverage to evidence development, an option increasingly used for new treatments with limited/uncertain evidence. There has been little effort to reconcile the features of technologies with the available options in a way that reflects purchasers’ ranges of authority

Original language	English
Place of Publication	York UK
Publisher	Centre for Health Economics, University of York
Number of pages	40
Volume	77
Publication status	Published - Apr 2012

Publication series

Name	CHE Research Paper
Publisher	Centre for Health Economics, University of York
No.	77

Keywords

health technology assessment
cost effectiveness
comparative effectiveness
only in research
coverage with evidence development
patient access scheme

Access to Document

CHERP77_a_framework_for_coverage_decisions_only_in_research_evidence_developmentFinal published version, 476 KB

https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP77_a_framework_for_coverage_decisions_only_in_research_evidence_development.pdf

Cite this

Walker, S. M., Sculpher, M., Claxton, K. P., & Palmer, S. J. (2012). Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. (CHE Research Paper; No. 77). Centre for Health Economics, University of York. https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP77_a_framework_for_coverage_decisions_only_in_research_evidence_development.pdf

@book{47787ac9d25842e089a0dc19b52939d2,

title = "Coverage with evidence development, only in research, risk sharing or patient access scheme?: A framework for coverage decisions",

abstract = "Until recently, purchasers{\textquoteright} options regarding whether to pay for the use of technologies have been binary in nature: a treatment is covered or not covered. However, policies have emerged which expand the options - for example, linking coverage to evidence development, an option increasingly used for new treatments with limited/uncertain evidence. There has been little effort to reconcile the features of technologies with the available options in a way that reflects purchasers{\textquoteright} ranges of authority",

keywords = "health technology assessment, cost effectiveness, comparative effectiveness, only in research, coverage with evidence development, patient access scheme",

author = "Walker, {Simon Mark} and Mark Sculpher and Claxton, {Karl Philip} and Palmer, {Stephen John}",

year = "2012",

month = apr,

language = "English",

volume = "77",

series = "CHE Research Paper",

publisher = "Centre for Health Economics, University of York",

number = "77",

}

Walker, SM , Sculpher, M , Claxton, KP & Palmer, SJ 2012, Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. CHE Research Paper, no. 77, vol. 77, Centre for Health Economics, University of York, York UK. <https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP77_a_framework_for_coverage_decisions_only_in_research_evidence_development.pdf>

TY - BOOK

T1 - Coverage with evidence development, only in research, risk sharing or patient access scheme?

T2 - A framework for coverage decisions

AU - Walker, Simon Mark

AU - Sculpher, Mark

AU - Claxton, Karl Philip

AU - Palmer, Stephen John

PY - 2012/4

Y1 - 2012/4

N2 - Until recently, purchasers’ options regarding whether to pay for the use of technologies have been binary in nature: a treatment is covered or not covered. However, policies have emerged which expand the options - for example, linking coverage to evidence development, an option increasingly used for new treatments with limited/uncertain evidence. There has been little effort to reconcile the features of technologies with the available options in a way that reflects purchasers’ ranges of authority

AB - Until recently, purchasers’ options regarding whether to pay for the use of technologies have been binary in nature: a treatment is covered or not covered. However, policies have emerged which expand the options - for example, linking coverage to evidence development, an option increasingly used for new treatments with limited/uncertain evidence. There has been little effort to reconcile the features of technologies with the available options in a way that reflects purchasers’ ranges of authority

KW - health technology assessment

KW - cost effectiveness

KW - comparative effectiveness

KW - only in research

KW - coverage with evidence development

KW - patient access scheme

M3 - Other report

VL - 77

T3 - CHE Research Paper

BT - Coverage with evidence development, only in research, risk sharing or patient access scheme?

PB - Centre for Health Economics, University of York

CY - York UK

ER -